Literature DB >> 22387058

Endogenous hyperinsulinaemia and exogenous insulin: a common theme between atherosclerosis, increased cancer risk and other morbidities.

Sarah E Holden, Craig J Currie.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22387058     DOI: 10.1016/j.atherosclerosis.2012.01.052

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


× No keyword cloud information.
  5 in total

1.  Transdermal delivery of insulin by amidated pectin hydrogel matrix patch in streptozotocin-induced diabetic rats: effects on some selected metabolic parameters.

Authors:  Silindile I Hadebe; Phikelelani S Ngubane; Metse R Serumula; Cephas T Musabayane
Journal:  PLoS One       Date:  2014-07-02       Impact factor: 3.240

2.  Randomized Trial of the Effects of Insulin and Metformin on Myocardial Injury and Stress in Diabetes Mellitus: A Post Hoc Exploratory Analysis.

Authors:  Pratyaksh K Srivastava; Aruna D Pradhan; Nancy R Cook; Paul M Ridker; Brendan M Everett
Journal:  J Am Heart Assoc       Date:  2017-12-23       Impact factor: 5.501

3.  Association between insulin resistance and post-ischaemic stroke outcome in patients without diabetes: protocol for a systematic review and meta-analysis.

Authors:  Jeremiah Hadwen; Woojin Kim; Brian Dewar; Tim Ramsay; Alexandra Davis; Dar Dowlatshahi; Michel Shamy
Journal:  BMJ Open       Date:  2021-03-26       Impact factor: 2.692

4.  Relationship among Insulin Therapy, Insulin Resistance, and Severe Coronary Artery Disease in Type 2 Diabetes Mellitus.

Authors:  Jing Song; Xinyi Xia; Ye Lu; Jing Wan; Haibing Chen; Jun Yin
Journal:  J Interv Cardiol       Date:  2022-09-26       Impact factor: 1.776

5.  Adding glimepiride to current insulin therapy increases high-molecular weight adiponectin levels to improve glycemic control in poorly controlled type 2 diabetes.

Authors:  Chun-Jun Li; Jing-Yun Zhang; De-Min Yu; Qiu-Mei Zhang
Journal:  Diabetol Metab Syndr       Date:  2014-03-20       Impact factor: 3.320

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.